A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent Implant

Thomas N. Eade, Eric M. Horwitz, Karen Ruth, Mark K. Buyyounouski, David J. D'Ambrosio, Steven J. Feigenberg, David Y T Chen, Alan Pollack

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Purpose: To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and 125I transperineal permanent prostate seed implant (125I) for patients with low-risk prostate cancer. Methods and Materials: Between 1998 and 2004, a total of 374 low-risk patients (prostate-specific antigen < 10 ng/ml, T1c-T2b, Gleason score of 6 or less, and no neoadjuvant hormones) were treated at Fox Chase Cancer Center (216 IMRT and 158 125I patients). Median follow-up was 43 months for IMRT and 48 months for 125I. The IMRT prescription dose ranged from 74-78 Gy, and 125I prescription was 145 Gy. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicity was recorded by using a modified Radiation Therapy Oncology Group scale. Freedom from biochemical failure was defined by using the Phoenix definition (prostate-specific antigen nadir + 2.0 ng/ml). Results: Patients treated by using IMRT were more likely to be older and have a higher baseline American Urological Association symptom index score, history of previous transurethral resection of the prostate, and larger prostate volumes. On multivariate analysis, IMRT was an independent predictor of lower acute and late Grade 2 or higher GU toxicity and late Grade 2 or higher GI toxicity. Three-year actuarial estimates of late Grade 2 or higher toxicity were 2.4% for GI and 3.5% for GU by using IMRT compared with 7.7% for GI and 19.2% for GU for 125I, respectively. Four-year actuarial estimates of freedom from biochemical failure were 99.5% for IMRT and 93.5% for 125I (p = 0.09). Conclusions: The IMRT and 125I produce similar outcomes, although IMRT appears to have less acute and late toxicity.

Original languageEnglish
Pages (from-to)338-345
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume71
Issue number2
DOIs
StatePublished - Jun 1 2008
Externally publishedYes

Fingerprint

toxicity
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
grade
antigens
Prostate-Specific Antigen
Prescriptions
Prostate
Phoenix (AZ)
Transurethral Resection of Prostate
Radiation Oncology
hormones
Neoplasm Grading
estimates
seeds
Seeds
Multivariate Analysis
histories

Keywords

  • Brachytherapy
  • IMRT
  • Prostate cancer
  • Radiation therapy
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent Implant. / Eade, Thomas N.; Horwitz, Eric M.; Ruth, Karen; Buyyounouski, Mark K.; D'Ambrosio, David J.; Feigenberg, Steven J.; Chen, David Y T; Pollack, Alan.

In: International Journal of Radiation Oncology Biology Physics, Vol. 71, No. 2, 01.06.2008, p. 338-345.

Research output: Contribution to journalArticle

Eade, Thomas N. ; Horwitz, Eric M. ; Ruth, Karen ; Buyyounouski, Mark K. ; D'Ambrosio, David J. ; Feigenberg, Steven J. ; Chen, David Y T ; Pollack, Alan. / A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent Implant. In: International Journal of Radiation Oncology Biology Physics. 2008 ; Vol. 71, No. 2. pp. 338-345.
@article{7ecfcd7900424238af4a351f2f797df6,
title = "A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent Implant",
abstract = "Purpose: To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and 125I transperineal permanent prostate seed implant (125I) for patients with low-risk prostate cancer. Methods and Materials: Between 1998 and 2004, a total of 374 low-risk patients (prostate-specific antigen < 10 ng/ml, T1c-T2b, Gleason score of 6 or less, and no neoadjuvant hormones) were treated at Fox Chase Cancer Center (216 IMRT and 158 125I patients). Median follow-up was 43 months for IMRT and 48 months for 125I. The IMRT prescription dose ranged from 74-78 Gy, and 125I prescription was 145 Gy. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicity was recorded by using a modified Radiation Therapy Oncology Group scale. Freedom from biochemical failure was defined by using the Phoenix definition (prostate-specific antigen nadir + 2.0 ng/ml). Results: Patients treated by using IMRT were more likely to be older and have a higher baseline American Urological Association symptom index score, history of previous transurethral resection of the prostate, and larger prostate volumes. On multivariate analysis, IMRT was an independent predictor of lower acute and late Grade 2 or higher GU toxicity and late Grade 2 or higher GI toxicity. Three-year actuarial estimates of late Grade 2 or higher toxicity were 2.4{\%} for GI and 3.5{\%} for GU by using IMRT compared with 7.7{\%} for GI and 19.2{\%} for GU for 125I, respectively. Four-year actuarial estimates of freedom from biochemical failure were 99.5{\%} for IMRT and 93.5{\%} for 125I (p = 0.09). Conclusions: The IMRT and 125I produce similar outcomes, although IMRT appears to have less acute and late toxicity.",
keywords = "Brachytherapy, IMRT, Prostate cancer, Radiation therapy, Toxicity",
author = "Eade, {Thomas N.} and Horwitz, {Eric M.} and Karen Ruth and Buyyounouski, {Mark K.} and D'Ambrosio, {David J.} and Feigenberg, {Steven J.} and Chen, {David Y T} and Alan Pollack",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.ijrobp.2007.10.019",
language = "English",
volume = "71",
pages = "338--345",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent Implant

AU - Eade, Thomas N.

AU - Horwitz, Eric M.

AU - Ruth, Karen

AU - Buyyounouski, Mark K.

AU - D'Ambrosio, David J.

AU - Feigenberg, Steven J.

AU - Chen, David Y T

AU - Pollack, Alan

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Purpose: To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and 125I transperineal permanent prostate seed implant (125I) for patients with low-risk prostate cancer. Methods and Materials: Between 1998 and 2004, a total of 374 low-risk patients (prostate-specific antigen < 10 ng/ml, T1c-T2b, Gleason score of 6 or less, and no neoadjuvant hormones) were treated at Fox Chase Cancer Center (216 IMRT and 158 125I patients). Median follow-up was 43 months for IMRT and 48 months for 125I. The IMRT prescription dose ranged from 74-78 Gy, and 125I prescription was 145 Gy. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicity was recorded by using a modified Radiation Therapy Oncology Group scale. Freedom from biochemical failure was defined by using the Phoenix definition (prostate-specific antigen nadir + 2.0 ng/ml). Results: Patients treated by using IMRT were more likely to be older and have a higher baseline American Urological Association symptom index score, history of previous transurethral resection of the prostate, and larger prostate volumes. On multivariate analysis, IMRT was an independent predictor of lower acute and late Grade 2 or higher GU toxicity and late Grade 2 or higher GI toxicity. Three-year actuarial estimates of late Grade 2 or higher toxicity were 2.4% for GI and 3.5% for GU by using IMRT compared with 7.7% for GI and 19.2% for GU for 125I, respectively. Four-year actuarial estimates of freedom from biochemical failure were 99.5% for IMRT and 93.5% for 125I (p = 0.09). Conclusions: The IMRT and 125I produce similar outcomes, although IMRT appears to have less acute and late toxicity.

AB - Purpose: To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and 125I transperineal permanent prostate seed implant (125I) for patients with low-risk prostate cancer. Methods and Materials: Between 1998 and 2004, a total of 374 low-risk patients (prostate-specific antigen < 10 ng/ml, T1c-T2b, Gleason score of 6 or less, and no neoadjuvant hormones) were treated at Fox Chase Cancer Center (216 IMRT and 158 125I patients). Median follow-up was 43 months for IMRT and 48 months for 125I. The IMRT prescription dose ranged from 74-78 Gy, and 125I prescription was 145 Gy. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicity was recorded by using a modified Radiation Therapy Oncology Group scale. Freedom from biochemical failure was defined by using the Phoenix definition (prostate-specific antigen nadir + 2.0 ng/ml). Results: Patients treated by using IMRT were more likely to be older and have a higher baseline American Urological Association symptom index score, history of previous transurethral resection of the prostate, and larger prostate volumes. On multivariate analysis, IMRT was an independent predictor of lower acute and late Grade 2 or higher GU toxicity and late Grade 2 or higher GI toxicity. Three-year actuarial estimates of late Grade 2 or higher toxicity were 2.4% for GI and 3.5% for GU by using IMRT compared with 7.7% for GI and 19.2% for GU for 125I, respectively. Four-year actuarial estimates of freedom from biochemical failure were 99.5% for IMRT and 93.5% for 125I (p = 0.09). Conclusions: The IMRT and 125I produce similar outcomes, although IMRT appears to have less acute and late toxicity.

KW - Brachytherapy

KW - IMRT

KW - Prostate cancer

KW - Radiation therapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=43049160704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049160704&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2007.10.019

DO - 10.1016/j.ijrobp.2007.10.019

M3 - Article

VL - 71

SP - 338

EP - 345

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -